SCHEMBL13284232

SCHEMBL13284232

COc1cc(CO)c([N+](=O)[O-])cc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 2/20 0.50
ALOX15 P16050 2/20 0.47
ALOX12 P18054 1/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ALDH1A1 P00352 4/20 0.46
CYP2D6 P10635 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CYP3A4 P08684 3/20 0.43
CYP2C19 P33261 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TTR P02766 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
CYP1A2 P05177 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
PRKDC P78527 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13324857 0.94 SNCA (0.50) SNCAALOX15ALOX12NPC1RAB9A
SCHEMBL67755 0.88 RAB9A (0.57) ALOX15NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL29976361 0.88 RAB9A (0.57) ALOX15NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL19361400 0.84 NPC1 (0.47) ALOX15NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL1401369 0.83 ALDH1A1 (0.53) SNCAALOX15ALOX12SMN1; SMN2ALDH1A1
SCHEMBL4103613 0.81 ALDH1A1 (0.48) SNCAALOX15SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL9490282 0.81 SNCA (0.74) SNCAALOX15ALOX12SMN1; SMN2ALDH1A1
SCHEMBL13557414 0.80 SMN1; SMN2 (0.49) ALOX15NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL14410938 0.78 RAB9A (0.45) ALOX15NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL13946710 0.78 SMN1; SMN2 (0.45) ALOX15ALOX12NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112280227-A PVA plasticizer composition and PVA optical film 熊烈祥 2021-01-29 CN claimed
EP-4613290-A1 TARGETING MOLECULE-CELL COMPLEX AND PREPARATION METHOD THEREFOR TCI GENE INC (TW) 2025-09-10 EP disclosed
CN-119997986-A Target molecule-cell complex and preparation method thereof 大江基因医学股份有限公司 2025-05-13 CN disclosed
WO-2024094131-A1 TARGETING MOLECULE-CELL COMPLEX AND PREPARATION METHOD THEREFOR 大江基因医学股份有限公司 2024-05-10 WO disclosed
CN-112280227-A PVA plasticizer composition and PVA optical film 熊烈祥 2021-01-29 CN disclosed
US-20200190067-A1 PHOTO-SWITCHABLE CHEMICAL INDUCERS OF DIMERIZATION FOR CONTROL OF PROTEIN FUNCTION IN CELLS BY LIGHT MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2020-06-18 US disclosed
EP-3649122-A1 PHOTO-SWITCHABLE CHEMICAL INDUCERS OF DIMERIZATION FOR CONTROL OF PROTEIN FUNCTION IN CELLS BY LIGHT Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2020-05-13 EP disclosed
WO-2019008175-A1 PHOTO-SWITCHABLE CHEMICAL INDUCERS OF DIMERIZATION FOR CONTROL OF PROTEIN FUNCTION IN CELLS BY LIGHT MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2019-01-10 WO disclosed
EP-3424922-A1 PHOTO-SWITCHABLE CHEMICAL INDUCERS OF DIMERIZATION FOR CONTROL OF PROTEIN FUNCTION IN CELLS BY LIGHT Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2019-01-09 EP disclosed
US-20100190151-A1 FLUORESCENTLY LABELED NUCLEOSIDE TRIPHOSPHATES AND ANALOGS THEREOF FOR SEQUENCING NUCLEIC ACIDS CALIFORNIA INSTITUTE OF TECHNOLOGY 2010-07-29 US disclosed
US-20070117104-A1 Nucleotide analogs FLUIDIGM CORPORATION 2007-05-24 US disclosed
US-20070117103-A1 Nucleotide analogs FLUIDIGM CORPORATION 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117103-A1 Nucleotide analogs NT5C2, NT5C3B, NUDT1 SNCA 2220/4885ALOX15 4685/4885ALOX12 4682/4885
US-20070117104-A1 Nucleotide analogs NT5C2, NT5C3B, NUDT1 SNCA 2220/4885ALOX15 4685/4885ALOX12 4682/4885
US-20200190067-A1 PHOTO-SWITCHABLE CHEMICAL INDUCERS OF DIMERIZATION FOR CONTROL OF PROTEIN FUNCTION IN CELLS BY LIGHT EDF1, ARFGEF1, PPIG SNCA 4680/4885ALOX15 4498/4885ALOX12 4499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.